Business Wire

Shippeo Tops 103% Annual Growth, Becomes World's Most Recommended Real-time Transportation Visibility Provider

13.10.2021 14:10:00 EEST | Business Wire | Press release

Share

Shippeo, a global leader and European specialist in real-time transportation visibility, announced today 103% year-on-year growth in subscription revenues and 181% net retention rate. The visibility solutions provider maintains the fastest growing customer base in Europe, having expanded its presence globally with the acquisition of several new high-profile customers currently being deployed in North America, Latin America, and APAC.

Since January, Shippeo has welcomed several new large international brands, including Coca-Cola HBC, one of the largest strategic bottling partners of The Coca-Cola Company; Nexans, a global player in energy transition; XPO Logistics, an American freight transportation company; and Woco Group, a global automotive component specialist, who supplies major OEMs.

A number of other category-leading brands have also chosen Shippeo’s real-time visibility solution, including Sappi, a leading producer of coated graphic paper, packaging and specialty papers; Conad, an Italian retail brand operating one of the largest supermarket chains in Italy; Fnac Darty Group, a French multinational electrical retailing company; Studio Moderna, an e-commerce company primarily operating across Central and Eastern Europe; and IDS, a Dutch 4PL logistics control tower specialist.

“Our very high net retention rate is a direct result of customers choosing to take fuller advantage of our expanding product portfolio, which now includes dock visibility and paperless visibility. Our ocean visibility has also become particularly popular as factors including Covid, the Suez blockage, and a global shortage of containers only intensifies the focus on the performance of this critical transport mode,” says Lucien Besse, COO of Shippeo.

“Shippeo has been recognized with a 98% recommendation rate on Gartner Peer Insights by our customers as at October 13, 2021*. I’m particularly proud of this achievement. Nothing is more important to us than delivering value to our customers and this is a fantastic result,” says Besse.

Shippeo’s team has expanded to over 230, with more than 90 new team members joining since January. Shippeo is on track to have more than doubled its staff year-on-year by the end of 2021. In addition, a number of senior profiles joined the company, including Nicolas Doucet, Strategic Alliance Director, previously at PTV Group; Guy-Pascal Bourlard, Head of Quality Assurance, previously at Amazon; Olivier Marcellin, Product Director, previously at Criteo; Marius Neuhäuser, Head of Solution Consulting, Alessandro De Martini, Business Development Director Italy, previously Country Manager at Transporeon and Bas Kramer, Business Development Director Benelux.

Furthermore, Shippeo is now expanding its operations into North America. As part of this strategic expansion, the company has welcomed Christopher Mazza as Senior Vice President, International Growth who will be responsible for leading the company’s activities in the region and growing Shippeo’s customer base. Christopher has extensive experience in the transportation and logistics industry, having participated in the creation of ClearMetal where he played an integral role in business development before joining project44 following the company's acquisition.

Recently the company announced new strategic partnerships with Savoye, a leading designer and integrator of complete supply chain solutions, and Tesisquare, a leading provider of supply chain execution applications. Shippeo has also partnered with Siemens DL, a leading IT provider in global supply chain management solutions.

The collaborations aim to make it easier for customers to overcome transport management challenges by leveraging deep TMS integrations, making it simple to take advantage of real-time visibility’s many benefits.

“We’re incredibly proud of the momentum we’re experiencing and the fact that we’ve maintained 0% customer churn throughout the year,” says Besse. “It’s really thanks to our extremely dedicated teams, our holistic customer-centric approach and a focus on the quality of our solution implementations, relationships and accelerated time to value for customers.”

Learn more

*https://www.gartner.com/reviews/market/real-time-transportation-visibility platforms/vendor/shippeo/product/shippeo-visibility-platform

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of
Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Shippeo
Audrey Emanuel
audrey.emanuel@shippeo.com
+33 6 17 33 36 47

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye